Dr. Hannah Uckelmann’s Max-Eder junior research group focuses on studying the epigenetic regulation of self-renewal programs during cancer development and the discovery of new therapeutics.

Dr. Uckelmann received her master’s degree in Molecular Biosciences from the university of Heidelberg studying long-noncoding RNAs in liver cancer in the group of Prof. Sven Diederichs. She then moved on to pursue her PhD with Prof. Andreas Trumpp and Prof. Marieke Essers at the German Cancer Research Center (DKFZ) in Heidelberg, where she investigated the response of hematopoietic stem cells to inflammatory stress.

For her postdoctoral training, Dr. Uckelmann joined the group of Prof. Scott Armstrong at the Dana-Farber Cancer Institute in Boston where she worked on the disruption of NPM1c mediated leukemic self-renewal through targeted epigenetic therapy. She was able to show that disrupting the MLL-complex on chromatin using Menin-MLL inhibitors can prevent the development of leukemia in NPM1c-mutant mouse models and treat fully developed human leukemias derived from patient samples. This preclinical work led to the inclusion of NPM1 mutant patients in the ongoing clinical phase II trials for Menin-MLL inhibitors.